Interesting RARE Put And Call Options For August 2026

Ultragenyx Pharmaceutical (RARE) is highlighted for income-oriented option strategies: a $32.50 put (bid $7.00) implies a net cost basis of $25.50 if assigned versus the current stock price of $33.34, with the put ~3% OTM, a 68% probability to expire worthless and a 21.54% return on cash commitment (32.09% annualized) to the seller. On the call side, a $35.00 covered call (bid $7.90) is ~5% OTM and would produce a 28.67% total return if called at the August 2026 expiry or a 23.70% premium boost (35.31% annualized) if it expires worthless; implied volatilities are ~95–96% versus a trailing 12‑month volatility of 53%.

Analysis

Market structure: Elevated IV (95–96% vs 53% realized) makes option sellers immediate winners — institutions harvesting YieldBoost (21–35% pictured) while directional longs pay a volatility tax. Buyers of pure long equity in RARE (Ultragenyx) are disadvantaged versus opportunistic cash‑secured put/covered‑call sellers; options liquidity and wide spreads may amplify execution costs. Cross‑asset impact is limited but a sustained IV-rich biotech patch would lift VIX/variance products and increase demand for short‑volatility carry in rates‑sensitive hedge books.

Risk assessment: Tail risks are binary clinical/regulatory failures or surprise safety news that can move shares ±50% intraday; financing/dilution risk if cash runway <12 months forces equity raises. Immediate (days) risk: gamma around any announced readouts; short term (weeks–months): IV mean reversion risk of −30% to −50% compressing option premium; long term (quarters–years): fundamental commercial uptake, pricing and M&A determine realized returns. Hidden dependencies: assignment liquidity, tax/timing of assignment, and dealer delta-hedging that can exacerbate moves.

Trade implications: Direct actionable plays are option-selling carry (cash‑secured puts at $32.50, covered calls at $35 Aug‑2026) sized to 1–2% NAV with protective wings (buy $27.50 put) to cap downside. Relative trades: long RARE vs short XBI or IBB to isolate idiosyncratic outcome around a readout. If expecting binary upside, buy deep OTM calls before catalyst windows; otherwise harvest premium and plan to roll if IV collapses >30%.

Contrarian angles: Market may underprice successful readout upside — historical rare‑disease winners have rallied >100% post‑data — so pure premium sellers risk missing asymmetric upside. Conversely, selling premium without protective spreads is likely underpriced for true tail risk. Unintended consequence: aggressive assignment during rallies can force unwanted long exposure at $25.50 net cost; ensure capital readiness and tax planning.

Key Decisions for Investors

• Sell-to-open cash-secured put: RARE Aug‑2026 $32.50, size to cap max cash at risk = 1–2% of NAV (e.g., $1–2m on $100m NAV). Collect ~ $7.00; if assigned cost basis = $25.50. Protect tail by converting to a put spread: sell $32.50, buy $27.50 to limit downside and lock a defined risk/reward.
• Covered-call income: Acquire RARE shares (up to 1–2% NAV) and sell Aug‑2026 $35 calls collecting ~$7.90. Target hold-to-expiration or roll if RARE > $38 or implied vol compresses >30% (buy back calls if premium drops >50% to avoid leaving upside opportunistically).
• Volatility management / pair trade: Go long RARE equity (1% NAV) vs short XBI (equal dollar) to neutralize sector beta ahead of an expected catalyst within 3–6 months. Unwind within 10 trading days after the readout to capture idiosyncratic move and limit prolonged sector exposure.
• Risk guardrails: Do not sell naked puts beyond capital for assignment; set stop-loss on net-long exposure at −25% realized loss or buy protective $27.50 puts. Monitor FDA/data readout calendar and insider/partnership filings over next 30–90 days; if any catalyst date is confirmed, close short-dated sold options 5 business days prior.